| Quarterly Financials | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 0 | 0 | 286 | 165 | 119 | 144 | 160 |
| Expenses | 0 | 0 | 251 | 150 | 103 | 123 | 135 |
| EBITDA | 0 | 0 | 35 | 15 | 17 | 21 | 25 |
| Operating Profit % | 0 % | 0 % | 12 % | 9 % | 14 % | 14 % | 16 % |
| Depreciation | 0 | 0 | 3 | 2 | 1 | 2 | 2 |
| Interest | 0 | 0 | 14 | 8 | 7 | 8 | 11 |
| Profit Before Tax | 0 | 0 | 20 | 7 | 9 | 13 | 14 |
| Tax | 0 | 0 | 7 | 1 | 2 | 3 | 4 |
| Net Profit | 0 | 0 | 14 | 6 | 7 | 9 | 11 |
| EPS in ₹ | 0.00 | 0.00 | 29.09 | 12.71 | 14.33 | 19.98 | 22.19 |
Fredun Pharmaceuticals
Fredun Pharmaceuticals
1,796.60
+148.60
(9.02%)
Market Cap
964.04 Cr
PE Ratio
24.61
Volume
29,901.00
Day High - Low
1,842.00 - 1,672.00
52W High-Low
1,999.00 - 635.05
Key Fundamentals
Market Cap
964.04 Cr
EPS
33.66
PE Ratio
24.61
PB Ratio
3.72
Book Value
443.74
EBITDA
38.90
Dividend Yield
0.04 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
12.86
Debt to Equity
0.88
Actual
Company News
View All News
Fredun Pharmaceuticals announces earnings conference call on February 12, 2026 at 12:00 PM to discuss Q3FY26 results for quarter ended December 31, 2025.
Fredun Pharmaceuticals Limited has scheduled its board meeting for February 9, 2026, to consider and approve Q3FY26 unaudited financial results. Trading window closed until 48 hours post-declaration.
Fredun Pharmaceuticals EGM on Feb 16, 2026
Jan 19, 2026
Jan 19, 2026Fredun Pharmaceuticals schedules EGM for February 16, 2026 via video conference to appoint Ms. Pooja N. Sanghavi as Non-Executive Independent Director for five years.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,704.60 | #1 4,08,990.64 | 37.12 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 55.32 | |
6,113.50 | 1,62,294.22 | 64.36 | 9,712.00 | 18.67 | 2,191 | 35.10 | 46.83 | |
3,997.20 | 1,35,283.41 | 62.31 | 11,539.40 | 6.99 | 1,911 | 30.46 | 53.95 | |
1,342.50 | 1,08,443.36 | 23.71 | 28,409.50 | 7.12 | 5,291 | -57.18 | 37.12 | |
1,275.50 | 1,06,457.10 | 18.76 | 33,741.20 | 16.73 | 5,725 | -15.28 | 62.03 | |
2,196.80 | 1,00,349.56 | 22.79 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 57.64 | |
923.45 | 92,920.68 | #1 17.76 | 23,511.00 | 18.55 | 4,615 | 34.60 | 59.51 | |
2,081.90 | 85,941.89 | 47.15 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 44.00 | |
1,203.70 | 69,911.09 | 20.22 | 32,345.60 | 9.43 | 3,484 | 3.81 | 54.54 | |
5,750.50 | 68,755.85 | 28.20 | 13,458.30 | 3.70 | 2,216 | 10.98 | 55.04 |
Growth Rate
Revenue Growth
26.26 %
Net Income Growth
44.44 %
Cash Flow Change
96.95 %
ROE
14.72 %
ROCE
9.48 %
EBITDA Margin (Avg.)
4.01 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 |
| Fixed Assets | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 |
| Current Assets | 13 | 28 | 35 | 52 | 73 | 109 | 130 | 153 | 216 | 257 |
| Capital Work in Progress | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other Assets | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 |
| Total Liabilities | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 |
| Current Liabilities | 16 | 32 | 41 | 43 | 53 | 86 | 87 | 74 | 140 | 167 |
| Non Current Liabilities | 4 | 7 | 8 | 14 | 13 | 14 | 32 | 45 | 21 | 19 |
| Total Equity | 3 | 4 | 7 | 22 | 39 | 41 | 43 | 68 | 96 | 122 |
| Reserve & Surplus | 1 | 1 | 2 | 19 | 35 | 37 | 39 | 63 | 84 | 115 |
| Share Capital | 3 | 3 | 5 | 3 | 4 | 4 | 4 | 4 | 5 | 5 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | -2 |
| Investing Activities | -3 | -6 | -7 | -8 | -5 | -2 | -1 | -4 | -9 | -8 |
| Operating Activities | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | -0 |
| Financing Activities | 1 | 4 | 3 | -8 | 4 | 14 | -1 | 8 | 25 | 6 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Nov 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | May 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Apr 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 52.04 % | 52.04 % | 52.04 % | 51.27 % | 51.27 % | 51.27 % | 51.04 % | 51.04 % | 50.34 % | 50.15 % | 49.62 % | 49.62 % | 49.33 % | 49.31 % | 49.16 % | 49.17 % | 48.92 % | 49.17 % | 48.93 % | 48.93 % | 48.93 % | 48.93 % | 48.93 % | 43.06 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.46 % |
| DIIs | 1.88 % | 1.88 % | 1.88 % | 1.69 % | 1.69 % | 1.69 % | 1.68 % | 1.68 % | 1.66 % | 1.65 % | 1.64 % | 1.64 % | 1.61 % | 1.60 % | 1.60 % | 1.60 % | 1.59 % | 1.60 % | 1.59 % | 1.59 % | 1.59 % | 1.59 % | 1.60 % | 3.48 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 41.01 % | 40.99 % | 40.77 % | 41.56 % | 41.90 % | 41.81 % | 42.02 % | 42.08 % | 42.48 % | 43.07 % | 43.64 % | 43.60 % | 43.48 % | 43.49 % | 43.67 % | 44.02 % | 43.94 % | 43.89 % | 44.21 % | 44.55 % | 44.50 % | 44.52 % | 43.74 % | 45.18 % |
| Others | 5.07 % | 5.09 % | 5.32 % | 5.47 % | 5.13 % | 5.23 % | 5.25 % | 5.19 % | 5.52 % | 5.13 % | 5.10 % | 5.14 % | 5.58 % | 5.60 % | 5.58 % | 5.22 % | 5.55 % | 5.35 % | 5.27 % | 4.93 % | 4.98 % | 4.96 % | 5.72 % | 7.83 % |
| No of Share Holders | 0 | 1,993 | 2,301 | 3,681 | 3,674 | 3,573 | 3,620 | 3,678 | 3,901 | 4,521 | 4,609 | 4,625 | 4,627 | 4,635 | 6,315 | 7,507 | 6,840 | 7,511 | 8,018 | 8,121 | 7,976 | 7,906 | 8,120 | 8,765 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.6 | 1 | 0.65 | 0.66 | 0.7 | 0.7 | 0.7 | 0.7 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.42 | 0.24 | 0.56 | 0.14 | 0.08 | 0.09 | 0.1 | 0.1 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 16 Feb 2026 |  Extraordinary General Meeting | NA | 16 Feb 2026 | 1,495.45 | 1,648.00 |
| 09 Feb 2026 |  Quarterly Result Announcement | NA | 09 Feb 2026 | 1,489.50 | 1,648.00 |
| 18 Sept 2021 |  Dividend | ₹ 0.70 /share | 16 Sept 2021 | 415.70 | 454.45 |
| 22 Sept 2023 | Dividend | ₹ 0.70 /share | 22 Sept 2023 | 886.50 | 875.65 |
| 18 Jan 2024 | Extraordinary General Meeting | NA | 18 Jan 2024 | 872.05 | 837.70 |
| 23 Sept 2024 | Dividend | ₹ 0.70 /share | 23 Sept 2024 | 981.65 | 767.60 |
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 788.20 | 755.65 |
| 26 Oct 2024 | Quarterly Result Announcement | NA | 26 Oct 2024 | 774.70 | 726.85 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 700.70 | 721.85 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 724.55 | 771.00 |
| 30 Jul 2025 | Quarterly Result Announcement | NA | 30 Jul 2025 | 860.20 | 958.60 |
| 23 Sept 2025 | Dividend | ₹ 0.70 /share | 23 Sept 2025 | 771.65 | 1,216.75 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 1,211.90 | 1,309.50 |
| 22 Oct 2025 | Extraordinary General Meeting | NA | 22 Oct 2025 | 1,306.50 | 1,660.80 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 1,723.30 | 1,551.30 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 hr ago
1 hr agoUn-Audited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 20255 hrs ago
5 hrs agoBoard Meeting Outcome for Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 20255 hrs ago
5 hrs agoBoard Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Monday 09Th February 20269 days ago
9 days agoNotice Of Book Closure For The Purpose Of Extra Ordinary General Meeting (EGM)Jan 20, 2026
Jan 20, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 20, 2026
Jan 20, 2026 Notice Convening Extra-Ordinary General Meeting (EGM) Of Fredun Pharmaceuticals LimitedJan 19, 2026
Jan 19, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 15, 2026
Jan 15, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2026
Jan 13, 2026Closure of Trading WindowDec 31, 2025
Dec 31, 2025Announcement under Regulation 30 (LODR)-AllotmentDec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-AllotmentDec 29, 2025
Dec 29, 2025Corrigendum Through General Announcement Regarding Disclosure Of Pre-Preferential Shareholding Of Proposed Allottees Ultimate Beneficial Owners (Ubos) Revised Issue Size Of Proposed Preferential Allotment Revised List Of Allottees And Bifurcation And BrieDec 18, 2025
Dec 18, 2025Corrigendum Through General Announcement Regarding Disclosure Of Pre-Preferential Shareholding Of Proposed Allottees Ultimate Beneficial Owners (Ubos) Revised Issue Size Of Proposed Preferential Allotment Revised List Of Allottees And Bifurcation And BrieDec 18, 2025
Dec 18, 2025Intimation Of Outcome Of Analysts/Investors Meeting Under The SEBI (Listing Obligations And Disclosures Requirements) Regulation 2015Dec 17, 2025
Dec 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 11, 2025
Dec 11, 2025Corrigendum Through General Announcement Regarding Disclosure Of Ultimate Beneficial Owners (Ubos) Pre -Preferential Shareholding Of Proposed Allottees And Bifurcation And Brief Description Of The Object In Connection With The Extra-Ordinary General MeetiNov 29, 2025
Nov 29, 2025Appointment of Company Secretary and Compliance OfficerNov 28, 2025
Nov 28, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateNov 28, 2025
Nov 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementNov 28, 2025
Nov 28, 2025General Announcement Pertaining To Disclosure Of Ultimate Beneficial Owners (Ubos) Of Proposed Allottees In Connection With The Extra-Ordinary General Meeting (EGM) Held On October 22 2025.Nov 15, 2025
Nov 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 14, 2025
Nov 14, 2025Audio Recording Of The Q2 FY26 Earnings Conference CallNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 10, 2025
Nov 10, 2025Revised Outcome Of Board MeetingNov 09, 2025
Nov 09, 2025Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerNov 08, 2025
Nov 08, 2025Outcome Of Board MeetingNov 08, 2025
Nov 08, 2025Board Meeting Outcome for Outcome Of Board Meeting.Nov 08, 2025
Nov 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2025
Nov 06, 2025Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Saturday 08Th November 2025Oct 28, 2025
Oct 28, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportOct 22, 2025
Oct 22, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMOct 22, 2025
Oct 22, 2025Corrigendum I To The Notice Of Extraordinary General Meeting.Oct 17, 2025
Oct 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 13, 2025
Oct 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 11, 2025
Oct 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 09, 2025
Oct 09, 2025Announcement under Regulation 30 (LODR)-CessationOct 06, 2025
Oct 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Oct 01, 2025Intimation Of Record Date For The Purpose Of EOGM Of The Company.Sep 30, 2025
Sep 30, 2025Notice Of Book Closure For The Purpose Of Extra Ordinary General Meeting To Be Held On 22Nd October 2025.Sep 30, 2025
Sep 30, 2025Notice Convening Extra-Ordinary General Meeting (EOGM) Of Fredun Pharmaceuticals LimitedSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2025
Sep 30, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 27, 2025
Sep 27, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th September 2025 Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Sep 25, 2025
Sep 25, 2025Closure of Trading WindowSep 22, 2025
Sep 22, 2025Technical Indicators
RSI(14)
Neutral 59.06
ATR(14)
Less Volatile 90.58
STOCH(9,6)
Overbought 84.40
STOCH RSI(14)
Overbought 96.17
MACD(12,26)
Bullish 25.99
ADX(14)
Weak Trend 14.96
UO(9)
Bearish 66.01
ROC(12)
Uptrend And Accelerating 11.89
WillR(14)
Overbought -16.25
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
